Literature DB >> 719696

Enhanced post-irradiation recovery of the haemopoietic system in animals pretreated with a variety of cytotoxic agents.

J L Millar, N M Blackett, B N Hudspith.   

Abstract

It is known that pretreatment of mice with bacterial endotoxin and certain stathmokinetic agents between 1 and 3 days prior to exposure to ioninzing radiation reduce radiation lethality. In this communication it is shown that pretreatment with cytosine arabinoside, methotrexate, nortestosterone and chlorambucil reduces radiation (1000 rad) induced lethality. This reduction can be ascribed to enhanced regeneration of the haemopoietic system in pretreated animals and not to increased survival of colony-forming cells (CFU) in these animals. Regeneration of CFUs was underway within 24 hr after 900 rad in the pretreated mice but did not start until day 3 in mice treated with gamma radiation only. Two agents, namely radiation itself (either 75 or 150 rad) and busulphan (10 mg/kg) did not reduce the lethal effects of subsequent gamma irradiation nor enhance the regeneration of CFUs, even though radiation, like the protective cytosine arabinoside, induces early CFUs proliferation. The administration of nucleoside precursors of DNA enhanced regrowth of haemopoietic stem cells to an extent comparable with that of the most effective pretreatment, cytosine arabinoside. It is postulated that drugs like cytosine arabinoside operate by causing cell death, providing a source of DNA that con enhance the regrowth of surviving stem cells in the bone marrow.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 719696     DOI: 10.1111/j.1365-2184.1978.tb00826.x

Source DB:  PubMed          Journal:  Cell Tissue Kinet        ISSN: 0008-8730


  21 in total

1.  Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.

Authors:  J Mansi; E Ellis; C Viner; J Mundy; T Smith; J Millar; S Milan; M Gore; D Cunningham
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Influence of scheduling on two-drug combinations of alkylating agents in vivo.

Authors:  B A Teicher; S A Holden; S M Jones; J P Eder; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer.

Authors:  D J Perez; T J Powles; I E Smith; M D Vincent; S Ashley; C Gordon; J Gibb; S Clarke; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Inhibition of growth and metastasis of syngeneic transplantable tumours by an aromatic retinoic acid analogue. 2. T cell dependence of retinoid effects in vivo.

Authors:  S A Eccles; H P Purvies; S C Barnett; P Alexander
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.

Authors:  P J Selby; J L Millar; T A Phelps; M Y Gordon; R Wilkinson; T J McElwain
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinoma.

Authors:  R J Fergusson; J Carmichael; J F Smyth
Journal:  Thorax       Date:  1986-05       Impact factor: 9.139

7.  Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.

Authors:  A Zimber; K Perk; I Livnat
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

8.  Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.

Authors:  B A Robinson; R D Clutterbuck; J L Millar; T J McElwain
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

9.  A human testicular teratoma serially transplanted in immune-deprived mice.

Authors:  P J Selby; E Heyderman; J Gibbs; M J Peckham
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

10.  High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice.

Authors:  B D Evans; I E Smith; J L Millar
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.